569 related articles for article (PubMed ID: 26095439)
1. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
Divekar R; Butterfield J
Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
[TBL] [Abstract][Full Text] [Related]
2. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A; Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
[TBL] [Abstract][Full Text] [Related]
3. Increased leukotriene E4 excretion in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):73-6. PubMed ID: 20380889
[TBL] [Abstract][Full Text] [Related]
4. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
Butterfield JH
Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
[TBL] [Abstract][Full Text] [Related]
5. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
Taylor ML; Sehgal D; Raffeld M; Obiakor H; Akin C; Mage RG; Metcalfe DD
J Mol Diagn; 2004 Nov; 6(4):335-42. PubMed ID: 15507672
[TBL] [Abstract][Full Text] [Related]
6. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
7. Clonal mast cell proliferation in pruriginous skin in hypereosinophilic syndrome.
Wiednig M; Beham-Schmid C; Kranzelbinder B; Aberer E
Dermatology; 2013; 227(1):67-71. PubMed ID: 24008407
[TBL] [Abstract][Full Text] [Related]
8. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
Butterfield JH; Weiler CR
Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
[TBL] [Abstract][Full Text] [Related]
9. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.
Bonadonna P; Perbellini O; Passalacqua G; Caruso B; Colarossi S; Dal Fior D; Castellani L; Bonetto C; Frattini F; Dama A; Martinelli G; Chilosi M; Senna G; Pizzolo G; Zanotti R
J Allergy Clin Immunol; 2009 Mar; 123(3):680-6. PubMed ID: 19135713
[TBL] [Abstract][Full Text] [Related]
10. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis.
Oranje AP; Mulder PG; Heide R; Tank B; Riezebos P; van Toorenenbergen AW
Clin Exp Dermatol; 2002 Sep; 27(6):502-6. PubMed ID: 12372095
[TBL] [Abstract][Full Text] [Related]
11. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis.
van Toorenenbergen AW; Oranje AP
Clin Chim Acta; 2005 Sep; 359(1-2):72-7. PubMed ID: 15913591
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
14. Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects.
Vos BJ; van der Veer E; van Voorst Vader PC; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; de Monchy JG; van Doormaal JJ; Oude Elberink JN
J Allergy Clin Immunol; 2015 Mar; 135(3):792-8. PubMed ID: 25129675
[TBL] [Abstract][Full Text] [Related]
15. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.
Sperr WR; Jordan JH; Fiegl M; Escribano L; Bellas C; Dirnhofer S; Semper H; Simonitsch-Klupp I; Horny HP; Valent P
Int Arch Allergy Immunol; 2002 Jun; 128(2):136-41. PubMed ID: 12065914
[TBL] [Abstract][Full Text] [Related]
16. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis.
Berezowska S; Flaig MJ; Ruëff F; Walz C; Haferlach T; Krokowski M; Kerler R; Petat-Dutter K; Horny HP; Sotlar K
Mod Pathol; 2014 Jan; 27(1):19-29. PubMed ID: 23807778
[TBL] [Abstract][Full Text] [Related]
17. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
[TBL] [Abstract][Full Text] [Related]
18. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
19. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Møller MB; Broesby-Olsen S;
Am J Hematol; 2014 May; 89(5):493-8. PubMed ID: 24443360
[TBL] [Abstract][Full Text] [Related]
20. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.
van Doormaal JJ; van der Veer E; van Voorst Vader PC; Kluin PM; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; Oude Elberink JN; de Monchy JG
Allergy; 2012 May; 67(5):683-90. PubMed ID: 22435702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
